Novavax Inc (NASDAQ:NVAX) reported the promotion of Mr. John J. Trizzino to SVP, Chief Financial Officer (CFO) and Chief Business Officer (CBO). Trizzino has been working as SVP, Commercial Operations, since 2014. As Chief Business Officer, he is now accountable for all commercial and pre-commercial launch execution and strategy as well as public relations. As Chief Financial Officer, he will be responsible for corporate funding, investor relations and financial reporting.
Stanley C. Erck, the CEO and President of Novavax, expressed that at this major inflection point for company, during which they are preparing to become a commercial firm, John marks as the right person to take into this expanded role. John’s history as a remarkable executive leader together with his background in business/commercial development and financial/corporate operations will play a vital role as they continue to advance the clinical development of their pipeline of vaccines towards the industry.
Mr. Trizzino first joined company in 2009 with an extensive range of experiences in small-to-large publicly-held firms. He has background in the vaccine industry with previous roles looking after commercialization, strategic development, financing, vaccine policy, investor relations and public relations, and business development.
During his role as Chief Executive Officer of Immunovaccine Inc., Trizzino successfully directed the firm into clinical advancement of its major candidate, while successfully obtaining the needed funding commitments in the equity segment and non-dilutive sources. Prior to his roles at Immunovaccine and Novavax, Mr. Trizzino also held leadership responsibilities at various other firms including MedImmune, LLC.
Mr. Trizzino expressed that with Novavax set to bring the world’s preliminary RSV vaccine to industry as they in parallel, work on their seasonal NanoFlu influenza vaccines, he is thrilled to assume this expanded profile that comprises leading their financial strategy and driving investor interest. He is proud to be included in the Novavax team that has led them to this point and anticipate advancing their development measures for the combined benefit of international public health and the firm’s financial success.